A recombinant Escherichia coli with high production of 2'-fucosyllactose and its construction method and application
By constructing a recombinant strain of Escherichia coli that produces high levels of 2′-fucosylated lactose, the problem of insufficient yield in existing technologies has been solved, and efficient production of 2′-fucosylated lactose has been achieved, with yields reaching 11.1 g/L in shake flasks and 46 g/L in fermenters, meeting industrial requirements.
Patent Information
- Application Number
- CN202410284614.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-13
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-03-13
AI Technical Summary
In the current technology, the yield of 2′-fucosylated lactose in Escherichia coli still cannot meet the needs of industrial production and needs to be further improved.
By introducing and replacing specific genes in Escherichia coli, a recombinant strain that produces high levels of 2′-fucosylated lactose was constructed. This included overexpressing genes for the de novo synthesis pathway of GDP-L-fucose, integrating fucosyltransferase genes, knocking out competing pathway genes, overexpressing genes for the pentose phosphate pathway and the GTP regeneration pathway, and weakening the promoter of the purA gene. Fermentation conditions were optimized to increase the yield of 2′-fucosylated lactose.
After 72 hours of fermentation in shake flasks, the yield of 2′-fucosylated lactose reached 11.1 g/L, and after 72 hours of fermentation in a 5L fermenter, the yield reached 46 g/L, which significantly improved the yield and met the needs of industrial production.
Smart Images

Figure BDA0004738692030000051 
Figure BDA0004738692030000061 
Figure BDA0004738692030000071
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of metabolic engineering, and in particular to a recombinant Escherichia coli with high 2'-fucosyllactose production, and a construction method and application thereof. Background Art
[0002] Human milk oligosaccharides (HMOs) are one of the most abundant solid components in breast milk besides lactose and fat. There are many types of HMOs. Currently, more than 200 HMOs with confirmed structures in breast milk are represented by 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3′-FL), lactose-N-tetraose (LNT), 3'-sialyllactose (3′-SL) and 6'-sialyllactose (6′-SL). Among them, 2′-fucosyllactose (2′-FL) is a trisaccharide formed by lactose and fucose through α-(1,2)-linkage. It is the most abundant fucosylated oligosaccharide, accounting for more than 30% of the total HMOs.
[0003] As a prebiotic, 2′-fucosyllactose (2′-FL) can regulate the intestinal microecology of infants; prevent pathogens from adhering to the intestines; have immunomodulatory effects, promote brain nerve development; and effectively prevent necrotizing enterocolitis. Due to its important physiological functions, people mostly introduce 2′-FL into infant formula. With the advancement of science and technology and the deepening of clinical research, people have found that 2′-FL not only has a great impact on the growth and development of infants and young children, but also has the effects of supplementing nutrition, aiding digestion, and promoting health for adults. It can be widely used in functional foods, dietary supplements, functional fortified beverages, infant formula milk powder, and special medical foods. In view of the potential value of 2′-FL in nutrition, health care, and pharmaceutical applications, efficient and economical production of 2′-FL has become a research hotspot. Although a variety of methods for large-scale production of 2′-FL have been established: chemical method, chemical-enzymatic method, and biosynthesis method. However, chemical synthesis is not suitable for meeting the production needs of 2′-FL due to the complex multiple protection and deprotection steps and low yield; in the enzymatic synthesis method, the catalytic synthesis of 2′-FL requires expensive GDP-L-Fuc precursor reagents, the enzyme catalytic activity is low, the synthesis amount is small, and it cannot meet the needs of industrial production of 2′-FL; while the biological de novo synthesis method has the characteristics of mild conditions, low cost, and environmental friendliness. Therefore, the biological synthesis method is more conducive to the large-scale production of 2′-FL.
[0004] As a precursor substrate of 2′-FL, GDP-L-fucose plays an important role in the metabolic pathway. Intracellular GDP-L-fucose synthesis generally includes two typical pathways: de novo pathway and salvage pathway. The de novo pathway is mainly based on the original sugar metabolism pathway of Escherichia coli, and constructs a de novo synthesis pathway of GDP-fucose with glucose as raw material, starting from the intracellular metabolite fructose 6-phosphate. Subsequently, three enzymes, phosphomannose isomerase (manA), phosphomannose mutase (manB) and mannose-1-phosphate guanyl transferase (manC), catalyze the conversion of fructose 6-phosphate into mannose 6-phosphate through a continuous cascade reaction. Mannose 6-phosphate is further catalyzed by enzymes encoded by GDP-mannose-6-dehydrogenase (gmd) and GDP-fucose synthase (flc) to generate GDP-fucose (GDP-L-fucose). The salvage pathway was originally derived from the metabolic system of mammalian cells and some Bacteroidetes. The pathway starts with L-fucose, and the extracellular L-fucose is transferred into the cell, and then GDP-L-fucose is synthesized through the catalytic action of L-fucokinase and GDP-L-fucose pyrophosphorylase (fkp). Finally, 2′-fucosyllactose is synthesized through the action of α-(1,2)-fucosyltransferase (futC) with GDP-fucose and lactose as substrates.
[0005] At present, the biosynthetic pathway of 2′-FL is mostly constructed in host bacteria such as Escherichia coli, Bacillus subtilis, Saccharomyces cerevisiae and Yarrowia lipolytica. Among them, due to the advantages of short growth cycle and simple culture conditions of Escherichia coli, most studies are to transform or optimize the intracellular synthesis pathway of GDP-L-fucose in Escherichia coli. However, in order to better meet the needs of 2′-FL industrial production, the yield of 2′-FL still needs to be further improved. Summary of the invention
[0006] The purpose of the present invention is to provide a recombinant Escherichia coli with high 2'-fucosyllactose production, and a construction method and application thereof.
[0007] In order to achieve the above object, the present invention first provides a method for constructing a recombinant bacterium producing 2′-fucosyllactose.
[0008] The method for constructing a 2'-fucosyllactose-producing recombinant bacterium provided by the invention comprises the steps of introducing manA gene, manB gene, manC gene, gmd gene, flc gene and futC gene into Escherichia coli.
[0009] The above method may further include the following steps: replacing the fliR gene in the Escherichia coli with the WbsJ gene, replacing the motA gene in the Escherichia coli with the WbgL gene, and replacing the flhD gene in the Escherichia coli with the Wcfb gene.
[0010] Furthermore, the method further comprises the following step: replacing the fliR gene, the motA gene and the flhD gene in the Escherichia coli with the futC gene.
[0011] Furthermore, the method further comprises the following steps: knocking out the lacZ gene, wcaJ gene, poxB gene and lon gene in the Escherichia coli, and replacing the treB gene in the Escherichia coli with the lac12 gene.
[0012] Furthermore, the method also includes the following steps: introducing the zwf gene, prs gene, gsk gene, gpt gene, gmk gene, ndk gene, purF gene, purHD gene, purC gene, purMN gene, purL gene and purEK gene into the Escherichia coli, knocking out the purR gene in the Escherichia coli, and weakening the purA gene in the Escherichia coli.
[0013] In the above method, the method for introducing manA gene, manB gene, manC gene, gmd gene, flc gene and futC gene into Escherichia coli can be carried out by introducing a DNA molecule containing manA gene, manB gene, manC gene, gmd gene, flc gene and futC gene or a recombinant plasmid containing the DNA molecule into Escherichia coli. The recombinant plasmid can be one or more. In a specific embodiment of the present invention, the manA gene, manB gene, manC gene, gmd gene, flc gene and futC gene are introduced into Escherichia coli through plasmid pCDF-Duet-manA-manB-manC-gmd and plasmid pACYC-Duet-flc-futC.
[0014] The replacement of the fliR gene in Escherichia coli with the WbsJ gene can be achieved by the integration fragment HAfliR-P11-WbsJ shown in Sequence 33 and the pTarget-fliR plasmid containing the sgRNA of the fliR gene.
[0015] The replacement of the motA gene in Escherichia coli with the WbgL gene can be achieved by the integration fragment HAmotA-P11-WbgL shown in Sequence 34 and the pTarget-motA plasmid containing the sgRNA of the motA gene.
[0016] The replacement of the flhD gene in Escherichia coli with the Wcfb gene is achieved by the integration fragment HAflhD-P11-Wcfb shown in sequence 35 and the pTarget-flhD plasmid containing the sgRNA of the flhD gene.
[0017] The replacement of the fliR gene in Escherichia coli with the futC gene can be achieved by integrating the fragment HAfliR-P11-futC shown in sequence 36 and the pTarget-fliR plasmid containing the sgRNA of the fliR gene.
[0018] The replacement of the motA gene in Escherichia coli with the futC gene can be achieved by the integration fragment HAflhD-P11-futC shown in Sequence 37 and the pTarget-flhD plasmid containing the sgRNA of the flhD gene.
[0019] The replacement of the flhD gene in Escherichia coli with the futC gene can be achieved by the integration fragment HAmotA-P11-futC shown in Sequence 38 and the pTarget-motA plasmid containing the sgRNA of the motA gene.
[0020] The treB gene in Escherichia coli is replaced by the lac12 gene by the integration fragment HAtreB-P shown in sequence 39. tac -lac12 and the pTarget-treB plasmid containing the sgRNA of the treB gene.
[0021] The knockout of the lacZ gene in Escherichia coli can be achieved by using the plasmid pTargetF-sg-lacZ and the homologous recombination fragment lacZ-UD.
[0022] The knockout of the wcaJ gene in Escherichia coli can be achieved by using the plasmid pTargetF-sg-wcaJ and the homologous recombination fragment wcaJ-UD.
[0023] The knockout of the poxB gene in Escherichia coli can be achieved by using the plasmid pTargetF-sg-poxB and the homologous recombination fragment poxB-UD.
[0024] The knockout of the lon gene in Escherichia coli can be achieved by using the plasmid pTargetF-sg-lon and the homologous recombination fragment lon-UD.
[0025] The zwf gene, prs gene, gsk gene, gpt gene, gmk gene, ndk gene, purF gene, purHD gene, purC gene, purMN gene, purL gene and purEK gene are introduced into the Escherichia coli by introducing a DNA molecule containing the zwf gene, prs gene, gsk gene, gpt gene, gmk gene, ndk gene, purF gene, purHD gene, purC gene, purMN gene, purL gene and purEK gene or a recombinant plasmid containing the DNA molecule into the Escherichia coli. The recombinant plasmid can be one or more. In a specific embodiment of the present invention, the zwf gene, prs gene, gsk gene, gpt gene, gmk gene, ndk gene, purF gene, purHD gene, purC gene, purMN gene, purL gene and purEK gene are introduced into Escherichia coli through plasmid pCDF-Duet-zwf-prs, plasmid pCDF-Duet-gsk-gpt-gmk-ndk, plasmid pACYC-Duet-purF-purHD-purC-purMN and plasmid pETDuet-purL-purEK.
[0026] The knockout of the purR gene in Escherichia coli can be achieved by using the plasmid pTargetF-sg-purR and the gene fragment purR.
[0027] The method for weakening the purA gene in Escherichia coli is to replace the promoter of the purA gene with the fliC promoter PfliC, which can be specifically achieved by the P1-Kan-PfliC-P2 fragment shown in Sequence No. 40 and the plasmid pKD46.
[0028] In the above method, the sequence of the manA gene is shown in Sequence 1 in the sequence list; the sequence of the manB gene is shown in Sequence 2 in the sequence list; the sequence of the manC gene is shown in Sequence 3 in the sequence list; the sequence of the gmd gene is shown in Sequence 4 in the sequence list; the sequence of the flc gene is shown in Sequence 5 in the sequence list; the sequence of the futC gene is shown in Sequence 6 in the sequence list; the sequence of the fliR gene is shown in Sequence 7 in the sequence list; the sequence of the WbsJ gene is shown in Sequence 8 in the sequence list; the sequence of the motA gene is shown in Sequence 9 in the sequence list; the sequence of the WbgL gene is shown in Sequence 10 in the sequence list; the sequence of the flhD gene is shown in Sequence 11 in the sequence list; the sequence of the Wcfb gene is shown in Sequence 12 in the sequence list; the sequence of the lacZ gene is shown in Sequence 13 in the sequence list; the sequence of the wcaJ gene is shown in Sequence 14 in the sequence list; the sequence of the poxB gene is shown in Sequence 15 in the sequence list; the sequence of the lon gene is shown in Sequence 16 in the sequence list; The sequence of the treB gene is shown in Sequence 17 in the sequence listing; the sequence of the lac12 gene is shown in Sequence 18 in the sequence listing; the sequence of the zwf gene is shown in Sequence 19 in the sequence listing; the sequence of the prs gene is shown in Sequence 20 in the sequence listing; the sequence of the gsk gene is shown in Sequence 21 in the sequence listing; the sequence of the gpt gene is shown in Sequence 22 in the sequence listing; the sequence of the gmk gene is shown in Sequence 23 in the sequence listing; the sequence of the ndk gene is shown in Sequence 24 in the sequence listing; the sequence of the purF gene is shown in Sequence 25 in the sequence listing; the sequence of the purHD gene is shown in Sequence 26 in the sequence listing; the sequence of the purC gene is shown in Sequence 27 in the sequence listing; the sequence of the purMN gene is shown in Sequence 28 in the sequence listing; the sequence of the purL gene is shown in Sequence 29 in the sequence listing; the sequence of the purEK gene is shown in Sequence 30 in the sequence listing; the sequence of the purR gene is shown in Sequence 31 in the sequence listing; and the sequence of the purA gene is shown in Sequence 32 in the sequence listing.
[0029] In any of the above methods, the Escherichia coli is E. coli BL21 (DE3) strain.
[0030] The recombinant bacteria constructed according to the above construction method also fall within the protection scope of the present invention.
[0031] In order to achieve the above object, the present invention further provides any one of the following M1)-M4) applications:
[0032] M1) Use of the recombinant bacteria constructed according to the above construction method in the production of 2′-fucosyllactose;
[0033] M2) Use of the recombinant bacteria constructed according to the above construction method to increase the production of 2′-fucosyllactose;
[0034] M3) Use of the recombinant bacteria constructed according to the above construction method in the preparation of products producing 2′-fucosyllactose;
[0035] M4) Use of the recombinant bacteria constructed according to the above construction method in the preparation of products with increased 2′-fucosyllactose production.
[0036] In order to achieve the above object, the present invention finally provides a method for producing 2′-fucosyllactose.
[0037] The method for producing 2'-fucosyllactose provided by the present invention comprises the following steps: fermenting and culturing the above-mentioned recombinant bacteria to obtain a fermentation product, wherein the fermentation product contains 2'-fucosyllactose.
[0038] Furthermore, the fermentation method may include the following steps: inoculating the above recombinant bacteria into a shake flask containing a fermentation medium, and culturing at 37°C until the OD 600nm When the pH value reached 0.6-0.8, IPTG (final concentration of 0.5 mM), substrate lactose (final concentration of 5 g / L) and L-fucose (final concentration of 2 g / L) were added, and the culture was carried out at 25°C (72 h) to obtain the fermentation product.
[0039] The fermentation culture method may also include the following steps: inoculating the above-mentioned recombinant bacteria into a fermentation tank containing a fermentation medium, culturing at 37°C and 300-750rpm until glycerol is exhausted, then adding IPTG (final concentration of 0.1mM) and substrate lactose (final concentration of 5g / L), and adding feed solution (glycerol and lactose are added in a uniform flow mode, the glycerol feeding rate is 4.5-11.0g / L / h, and the lactose feeding rate is 1.5-3.0g / L / h), and lowering the temperature to 25°C to enter fermentation culture. During the fermentation culture process, L-fucose (final concentration of 20mM) is added once every 12h, for a total of 4 times, and 50% ammonia water is used to adjust the pH to maintain at 6.5-7.0.
[0040] Furthermore, the solvent of the fermentation medium is water, the solutes and their concentrations are 20 g / L glycerol, 13.5 g / L potassium dihydrogen phosphate, 4.0 g / L diammonium hydrogen phosphate, 1.7 g / L citric acid, 1.4 g / L magnesium sulfate heptahydrate and 10 mL / L trace metal element solution, and the pH is adjusted to 6.8 with sodium hydroxide. The solvent of the trace metal element solution is 5M hydrochloric acid, and the solutes and their concentrations are 10 g / L ferrous sulfate, 2.25 g / L zinc sulfate heptahydrate, 1.0 g / L anhydrous copper sulfate, 0.35 g / L manganese sulfate monohydrate, 0.23 g / L sodium borate decahydrate, 0.11 g / L ammonium molybdate, and 2.0 g / L calcium chloride dihydrate.
[0041] The present invention provides a method for constructing a recombinant engineering bacterium with high 2′-fucosyllactose production, the method comprising the following steps of transforming Escherichia coli: overexpressing genes of a de novo synthesis pathway of GDP-L-fucose (manA gene, manB gene, manC gene, gmd gene, flc gene and futC gene), introducing fucosyltransferase genes from different sources (integrating WbsJ gene at the fliR site, integrating WbgL gene at the motA site, and integrating Wcfb gene at the flhD site), increasing the copy number of futC (integrating WbsJ gene at the fliR site, integrating WbgL gene at the motA site, and integrating Wcfb gene at the flhD site, respectively), and increasing the copy number of futC (integrating WbsJ gene at the fliR site, integrating WbsJ gene at the motA site, and integrating Wcfb gene at the flhD site, respectively). The futC gene was integrated at the site of the recombinant Escherichia coli (the futC gene was integrated at the treB site), the lactose transporter Lac12 was introduced (the lac12 gene was integrated at the treB site), the lacZ, wcaJ, poxB, and lon genes of the competition pathway were knocked out, the zwf and prs genes on the pentose phosphate pathway (PPP) were overexpressed, the GTP regeneration pathway genes (gsk, gpt, gmk, ndk) and their upstream purine operon genes (purF, purHD, purC, purMN, purL, purEK) were overexpressed, the purR gene was knocked out and the purA gene was weakened (the promoter of the purA gene was replaced with the fliC promoter PfliC). The recombinant Escherichia coli producing 2'-fucosyllactose constructed by the present invention can produce 11.1 g / L of 2'-FL after fermentation for 72 hours in a shake flask, and can produce 46 g / L of 2'-FL after fermentation for 72 hours in a 5L fermenter. DETAILED DESCRIPTION
[0042] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0043] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0044] The culture medium and formulations involved in the following examples are as follows:
[0045] LB liquid medium: 10 g / L peptone, 5 g / L yeast extract powder, 10 g / L sodium chloride.
[0046] LB solid medium: 10 g / L peptone, 5 g / L yeast extract powder, 10 g / L sodium chloride, 15 g / L agar powder.
[0047] The fermentation medium (Defined medium, DM) solvent is water, the solutes and their concentrations are 20g / L glycerol, 13.5g / L potassium dihydrogen phosphate, 4.0g / L diammonium hydrogen phosphate, 1.7g / L citric acid, 1.4g / L magnesium sulfate heptahydrate and 10mL / L trace metal element solution, and the pH is adjusted to 6.8 with sodium hydroxide. Among them, the trace metal element solution formula is as follows: 10g / L ferrous sulfate, 2.25g / L zinc sulfate heptahydrate, 1.0g / L anhydrous copper sulfate, 0.35g / L manganese sulfate monohydrate, 0.23g / L sodium borate decahydrate, 0.11g / L ammonium molybdate, 2.0g / L calcium chloride dihydrate, dissolved in 5M hydrochloric acid.
[0048] The primer sequences involved in the following examples are shown in Table 1.
[0049] Table 1. Primer sequences
[0050]
[0051]
[0052]
[0053] Example 1. Construction of E. coli BL21(DE3)-1 strain
[0054] The de novo GDP-L-fucose synthesis pathway genes manA, manB, manC, gmd, flc and futC were overexpressed in E. coli BL21 (DE3) to obtain the E. coli BL21 (DE3)-1 strain. The specific steps are as follows:
[0055] 1. Using E. coli BL21 (DE3) genomic DNA as a template, PCR amplification was performed using primers manA-F / R, manB-F / R, manC-F / R and gmd-F / R to obtain gene fragments of phosphomannose isomerase (manA), phosphomannose mutase (manB), α-D-mannose 1-phosphate guanyltransferase (manC), and GDP-mannose 4,6-dehydrogenase (gmd), respectively.
[0056] 2. The manA gene fragment and pCDF-Duet plasmid (Shanghai Qincheng Biotechnology Co., Ltd., catalog number QCP0052) were double-digested with BamHI / EcoRI. After the digestion product was purified by gel recovery, the obtained gene fragment and the digestion fragment of pCDF-Duet plasmid were connected overnight using DNA ligase. The ligation product was transformed into E.coli JM109 competent state by heat shock, screened with streptomycin resistance plates, and the transformants were selected for sequencing verification to obtain a successfully constructed plasmid, which was recorded as pCDF-Duet-manA. The manB gene fragment and pCDF-Duet-manA plasmid were double-digested with HindIII / NotI. After the digestion product was purified by gel recovery, the obtained manB gene fragment and the digestion fragment of pCDF-Duet-manA plasmid were connected overnight using DNA ligase. The ligation product was transformed into E. coli JM109 competent cells by heat shock, screened on streptomycin resistance plates, and the transformants were selected for sequencing verification to obtain a successfully constructed plasmid, which was recorded as pCDF-Duet-manA-manB.
[0057] The manC gene fragment and pCDF-Duet-manA-manB plasmid were double-digested with NdeI / EcoRV, and the digestion product was purified by gel recovery. The obtained manC gene fragment and the pCDF-Duet-manA-manB plasmid digestion fragment were connected overnight using DNA ligase. The ligation product was transformed into E.coli JM109 competent state by heat shock, screened with streptomycin resistance plates, and the transformants were selected for sequencing verification to obtain a successfully constructed plasmid, which was recorded as pCDF-Duet-manA-manB-manC.
[0058] The gmd gene fragment and the pCDF-Duet-manA-manB-manC plasmid were double digested with KpnI / XhoI, and the digestion product was recovered and purified by gel, and then the obtained gmd gene fragment and the pCDF-Duet-manA-manB-manC plasmid digestion fragment were connected overnight using DNA ligase; the ligation product was heat-shock transformed into E.coli JM109 competent state, screened on streptomycin resistance plates, and the transformants were picked for sequencing verification to obtain a successfully constructed plasmid, which was recorded as pCDF-Duet-manA-manB-manC-gmd.
[0059] 3. Using E. coli BL21 (DE3) genomic DNA as a template, primers flc-F / R were used for PCR amplification to obtain the gene fragment of GDP-L-fucose synthase (flc); according to the α-1,2-fucosyltransferase gene futC sequence of Helicobacter pylori (ATCC No. 26695) published on NCBI, Shanghai Bioengineering synthesized the futC sequence based on the codon preference of E. coli, and designed primers futC-F / R for PCR amplification to obtain the gene fragment of α-1,2-fucosyltransferase (futC).
[0060] 4. The flc gene fragment and pACYC-Duet plasmid (Shanghai Zeye Biotechnology Co., Ltd., catalog number ZY-61112) were double-digested with BamHI / EcoRI. After the digestion product was recovered and purified by gel, the obtained flc gene fragment and the pACYC-Duet plasmid digestion fragment were connected overnight using DNA ligase; the ligation product was transformed into E. coli JM109 competent state by heat shock, screened on streptomycin resistance plates, and the transformants were selected for sequencing to obtain a successfully constructed plasmid, which was named pACYC-Duet-flc.
[0061] The futC gene fragment and the pACYC-Duet-flc plasmid were double-digested with NdeI / EcoRV, and the digestion products were recovered and purified by gel, and then the obtained futC gene fragment and the pACYC-Duet-flc plasmid digestion fragment were ligated overnight using DNA ligase; the ligation product was heat-shock transformed into E. coli JM109 competent state, screened on streptomycin resistance plates, and the transformants were selected for sequencing to obtain a successfully constructed plasmid, which was named pACYC-Duet-flc-futC.
[0062] 5. The above plasmids pCDF-Duet-manA-manB-manC-gmd and pACYC-Duet-flc-futC were transformed into E. coli BL21 (DE3), and the engineered bacteria E. coli BL21 (DE3)-1 were obtained after identification.
[0063] Example 2: Construction of E. coli BL21(DE3)-2 strain
[0064] On the basis of E. coli BL21 (DE3) -1 strain, fucosyltransferase genes from different sources were introduced for integration expression (WbsJ gene was integrated at the fliR site, WbgL gene was integrated at the motA site, and Wcfb gene was integrated at the flhD site) to increase the expression level of the fucosyltransferase gene, and E. coli BL21 (DE3) -2 strain was obtained. The specific steps are as follows:
[0065] 1. Transform the pCas9 plasmid (Nanjing Yaoshunyu Biotechnology Co., Ltd., catalog number p-201--p-205) into E. coli BL21 (DE3) -1, spread on a plate containing 50 μg / mL of kanamycin, culture at 30 ° C for 12 hours, pick a single colony on the plate, inoculate it into fresh LB medium, add kanamycin antibiotics with a final concentration of 50 μg / mL, and culture at 30 ° C, 220r / min overnight; transfer the overnight cultured bacterial solution to a 250mL conical flask containing 50mL LB medium at an inoculum volume of 1%, and wait until the bacterial OD 600nm When the concentration reaches 0.2, add arabinose with a final concentration of 20-30 mmol / L to induce the pCas9 plasmid to express the recombinase; continue to culture until the OD 600nm When the p-value is 0.6-0.7, ice-bathe the bacterial solution for 20 minutes, and then collect the bacterial cells by centrifugation at 5000r / min; wash the cells twice with pre-cooled sterile water, pour off the supernatant, and suspend the cells with 400-500μL pre-cooled 10% glycerol to prepare E.coli BL21(DE3)-1 competent cells with pCas9 plasmid for later use.
[0066] 2. According to the WbsJ gene sequence of Escherichia coli (E. coli O128: B12, AAO37698.1) published on NCBI, primers fliR-F / R and WbsJ-F / R were designed, and the integration fragment HAfliR-P11-WbsJ consisting of the upstream and downstream homology arms of the flagellar kinesin gene fliR site, the P11 promoter and the fucosyltransferase gene WbsJ from Escherichia coli (E. coli O128: B12, AAO37698.1) was obtained by fusion PCR technology (the nucleotide sequence of the integration fragment HAfliR-P11-WbsJ is shown in SEQ ID NO: 33, wherein positions 1-1000 are the upstream homology arms, positions 1001-1020 are the P11 promoter sequence, positions 1021-1869 are the fucosyltransferase gene WbsJ sequence, and positions 1870-2869 are the nucleotide sequence of the fucosyltransferase gene WbsJ). The N20 sequence and N20-fliR-F / R primers of the fliR gene were designed using the website (https: / / 5chopchop.cbu.uib.no / ), and the pTarget plasmid (Shanghai Core Biotechnology Co., Ltd., catalog number #62226) was used as a template to perform PCR amplification using primers N20-fliR-F / R to obtain the pTarget-fliR plasmid containing the sgRNA of the fliR gene.
[0067] The above-obtained integration fragment HAfliR-P11-WbsJ and pTarget-fliR plasmid were co-transformed into the competent E. coli BL21 (DE3) -1 with pCas9 plasmid at a mass ratio of 2:1, and 800 μL of LB medium was immediately added. After culturing for 2 hours at 30°C and 220 r / min, the culture was spread on a plate containing kanamycin (50 μg / mL) and spectinomycin (50 μg / mL) antibiotics and cultured overnight at 30°C. By picking a single colony for PCR verification and DNA sequencing verification, it was confirmed that the fucosyltransferase gene WbsJ from different sources was successfully integrated into the flagellar motor protein gene fliR site of the Escherichia coli genome, and the engineered strain E. coli BL21 (DE3) -1 △ fliR:: WbsJ was obtained.
[0068] 3. According to the WbgL gene sequence of Escherichia coli (E.coli O126, ADN43847.1) published on NCBI, primers motA-F / R and WbgL-F / R were designed, and the upstream and downstream homologous arms of the flagellar kinesin gene motA site, the P11 promoter and the flagellar kinesin gene from E.coli ( O126, ADN43847.1) (the nucleotide sequence of the integrated fragment HAmotA-P11-WbgL is shown in SEQ ID NO: 34, wherein positions 1-995 are the upstream homology arm, positions 996-1015 are the P11 promoter sequence, positions 1016-1905 are the fucosyltransferase gene WbgL sequence, and positions 1906-2905 are the downstream homology arm); then the N20 sequence and N20-motA-F / R primers of the motA gene were designed using the website (https: / / 5chopchop.cbu.uib.no / ), and PCR amplification was performed using the N20-motA-F / R primers using the pTarget plasmid as a template to obtain the pTarget-motA plasmid containing the sgRNA of the motA gene.
[0069] The above-obtained integration fragment HAmotA-P11-WbgL and pTarget-motA plasmid were co-transformed into the competent E.coliBL21(DE3)-1△fliR::WbsJ with pCas9 plasmid at a mass ratio of 2:1, and 800μL of LB medium was immediately added. After culturing for 2h at 30℃ and 220r / min, the culture was spread on a plate containing kanamycin (50μg / mL) and spectinomycin (50μg / mL) antibiotics and cultured overnight at 30℃. By picking single colonies for PCR verification and DNA sequencing verification, it was confirmed that the fucosyltransferase gene WbgL from different sources was successfully integrated into the motA site of the flagellar motor protein gene in the Escherichia coli genome, and the engineered strain E.coliBL21(DE3)-1△fliR::WbsJ,△motA::WbgL was obtained.
[0070] 4. According to the Wcfb gene sequence of Bacteroides fragilis (CAH06753.1) published on NCBI, primers flhD-F / R and Wcfb-F / R were designed, and the integration fragment HAflhD-P11-Wcfb consisting of the upstream and downstream homology arms of the flagellar kinesin gene flhD site, the P11 promoter and the fucosyltransferase gene Wcfb from Bacteroides fragilis (CAH06753.1) was obtained by fusion PCR technology (the nucleotide sequence of the integration fragment HAflhD-P11-Wcfb is shown in SEQ ID NO:35, where the first -1000 is the upstream homology arm, 1001-1020 is the P11 promoter sequence, 1021-1881 is the fucosyltransferase gene Wcfb sequence, and 1882-2881 is the downstream homology arm); then the N20 sequence and N20-flhD-F / R primers of the flhD gene were designed using the website (https: / / 5chopchop.cbu.uib.no / ), and PCR amplification was performed using the primers N20-flhD-F / R with the pTarget plasmid as a template to obtain the pTarget-flhD plasmid containing the sgRNA of the flhD gene.
[0071] The integrated fragment HAflhD-P11-Wcfb obtained above and the pTarget-flhD plasmid were co-transfected into the competent cell of E. coli BL21 (DE3) -1△fliR::WbsJ,△motA::WbgL carrying the pCas9 plasmid at a mass ratio of 2:1, and 800 μL of LB medium was immediately added. After culturing at 30°C and 220 r / min for 2 h, the culture was spread on a plate containing kanamycin (50 μg / mL) and spectinomycin (50 μg / mL) antibiotics and cultured at 30°C overnight. By picking single colonies for PCR verification and DNA sequencing verification, it was confirmed that the fucosyltransferase gene Wcfb from different sources was successfully integrated into the flagellar motor protein gene flhD site of the Escherichia coli genome. Finally, the engineered bacteria E. coli BL21 (DE3) -1 △fliR:: WbsJ, △motA:: WbgL, △flhD:: Wcfb were constructed and recorded as E. coli BL21 (DE3) -2.
[0072] Example 3: Construction of E. coli BL21(DE3)-3 strain
[0073] Based on E. coli BL21(DE3)-2, the α-1,2-fucosyltransferase futC gene was additionally integrated into three sites (the futC gene was integrated into the fliR site, motA site, and flhD site, respectively) to increase the copy number of Helicobacter pylori futC, and the E. coli BL21(DE3)-3 strain was obtained. The specific steps are as follows:
[0074] 1. According to the α-1,2-fucosyltransferase futC gene sequence of Helicobacter pylori (ATCC No. 26695) published on NCBI, the integration fragment HAfliR-P11-futC consisting of the upstream and downstream homology arms of the flagellar kinesin gene fliR site, the P11 promoter and the α-1,2-fucosyltransferase gene futC was obtained by fusion PCR technology (the nucleotide sequence of the integration fragment HAfliR-P11-futC is shown in SEQ ID NO: 36, where positions 1-1000 are the upstream homology arms, positions 1001-1020 are the P11 promoters, and positions 1002-1013 are the P11 promoters). The N20 sequence of the fliR gene was selected from the website (https: / / 5chopchop.cbu.uib.no / ) and the primers N20-fliR-F / R were designed. The pTarget plasmid was used as a template and PCR amplification was performed with the primers N20-fliR-F / R to obtain the pTarget-fliR plasmid containing the sgRNA of the fliR gene.
[0075] According to the α-1,2-fucosyltransferase futC gene sequence of Helicobacter pylori (ATCC No. 26695) published on NCBI, the integration fragment HAflhD-P11-futC consisting of the upstream and downstream homology arms of the flagellar kinesin gene flhD site, the P11 promoter and the α-1,2-fucosyltransferase gene futC was obtained by fusion PCR technology (the nucleotide sequence of the integration fragment HAflhD-P11-futC is shown in SEQ ID NO: 37, wherein the 1st to 1000th positions are the upstream homology arms, the 1001st to 1020th positions are the P11 promoter). sequence, positions 1021-1903 are the futC gene sequence, and positions 1904-2903 are the downstream homology arms); then the N20 sequence of the flhD gene was selected and the primers N20-flhD-F / R were designed using the website (https: / / 5chopchop.cbu.uib.no / ), and PCR amplification was performed using the primers N20-flhD-F / R with the pTarget plasmid as a template to obtain the pTarget-flhD plasmid containing the sgRNA of the flhD gene.
[0076] According to the α-1,2-fucosyltransferase futC gene sequence of Helicobacter pylori (ATCC No. 26695) published on NCBI, the integration fragment HAMotA-P11-futC consisting of the upstream and downstream homology arms of the flagellar kinesin gene motA site, the P11 promoter and the α-1,2-fucosyltransferase gene futC was obtained by fusion PCR technology (the nucleotide sequence of the integration fragment HAMotA-P11-futC is shown in SEQ ID NO: 38, wherein the 1st to 991st positions are the upstream homology arms, and the 992nd to 1011th positions are the P11 promoter). sequence, positions 1012-1914 are the futC gene sequence, and positions 1915-2914 are the downstream homology arms); then the N20 sequence of the motA gene was selected and the primers N20-motA-F / R were designed using the website (https: / / 5chopchop.cbu.uib.no / ), and PCR amplification was performed using the primers N20-motA-F / R with the pTarget plasmid as a template to obtain the pTarget-motA plasmid containing the sgRNA of the motA gene.
[0077] 2. The integration fragment HAfliR-P11-futC obtained above and the pTarget-fliR plasmid were co-transfected into the competent cell of E. coli BL21(DE3)-2 carrying the pCas9 plasmid to obtain the engineered strain E. coli BL21(DE3)-2△fliR::futC in which the futC gene sequence was successfully integrated into the fliR site of the flagellar motor protein gene in the Escherichia coli genome.
[0078] 3. The integration fragment HAflhD-P11-futC obtained above and the pTarget-flhD plasmid were co-transfected into the competent cell of E. coli BL21 (DE3) -2△fliR::futC to obtain the engineered strain E. coli BL21 (DE3) -2△fliR::futC,△flhD::futC, in which the futC gene sequence was successfully integrated into the flagellar motor protein gene flhD site of the Escherichia coli genome.
[0079] 4. The integration fragment HAmotA-P11-futC obtained above and the pTarget-motA plasmid were co-transfected into the competent cell of E. coli BL21 (DE3) -2△fliR::futC,△flhD::futC to obtain the engineered strain E. coli BL21 (DE3) -2△fliR::futC,△flhD::futC,△motA::futC in which the futC gene sequence was successfully integrated into the flagellar motor protein gene motA site of the Escherichia coli genome, and named it E. coli BL21 (DE3) -3.
[0080] Example 4: Construction of E. coli BL21(DE3)-5 strain
[0081] 1. Construction of E. coli BL21(DE3)-4 strain
[0082] Based on the E. coli BL21 (DE3) -3 strain, the lactose transporter Lac12 was introduced (the lac12 gene was integrated into the treB site) to obtain the E. coli BL21 (DE3) -4 strain. The specific steps are as follows:
[0083] 1. According to the lactose transporter Lac12 of Kluyveromyces lactis (NC_006038.1) published on NCBI, primers treB-F / R and Lac12-F / R were designed, and the upstream and downstream homologous arms of the treB locus and the P tac The integration fragment consisting of the promoter and Lac12 gene HAtreB-P tac-lac12 (integrated fragment HAtreB-P tac The nucleotide sequence of -lac12 is shown in SEQ ID NO:39, where positions 1-1000 are the upstream homology arm, and positions 1001-1029 are P tac The promoter sequence, the 1030-2706th position is the Lac12 gene sequence, and the 2707-3706th position is the downstream homology arm); then the N20 sequence of the treB gene and the primers N20-treB-F / R were designed using the website (https: / / chopchop.cbu.uib.no / ), and the pTarget plasmid was used as a template and the primers N20-treB-F / R were used for PCR amplification to obtain the pTarget-treB plasmid containing the sgRNA of the treB gene.
[0084] 2. The integrated fragment HAtreB-P tac -lac12 and pTarget-treB plasmids were co-electroplated into the competent cell of E. coli BL21(DE3)-3 carrying the pCas9 plasmid, and the engineered strain E. coli BL21(DE3)-2△fliR::futC,△flhD::futC,△motA::futC,treB::Lac12 in which the gene sequence of the lactose transporter Lac12 was successfully integrated into the treB gene site of the E. coli genome was obtained, and it was named E. coli BL21(DE3)-4.
[0085] 2. Construction of E. coli BL21(DE3)-5 strain
[0086] Based on the E. coli BL21(DE3)-4 strain, CRISPR / Cas9 was used to knock out the lacZ, wcaJ, poxB, and lon genes in the competition pathway to obtain the E. coli BL21(DE3)-5 strain. The specific steps are as follows:
[0087] 1. Using E. coli BL21 (DE3) genomic DNA as a template, PCR amplification was performed using primers lacZ-US-F / R and lacZ-DS-F / R; wcaJ-US-F / R and wcaJ-DS-F / R; poxB-US-F / R and poxB-DS-F / R; lon-US-F / R and lon-DS-F / R to obtain the upstream and downstream fragments of the lacZ gene, the upstream and downstream fragments of the wcaJ gene, the upstream and downstream fragments of the poxB gene, and the upstream and downstream fragments of the lon gene, respectively. Then, the upstream and downstream fragments of lacZ gene, wcaJ gene, poxB gene and lon gene were used as templates, and overlapping PCR amplification was performed using primers lacZ-US-F / R and lacZ-DS-F / R; wcaJ-US-F / R and wcaJ-DS-F / R; poxB-US-F / R and poxB-DS-F / R; lon-US-F / R and lon-DS-F / R, respectively, to obtain the homologous recombination fragment lacZ-UD, the homologous recombination fragment wcaJ-UD, the homologous recombination fragment poxB-UD and the homologous recombination fragment lon-UD, respectively.
[0088] 2. Using the pTargetF plasmid as a template, PCR amplification was performed using primers ΔlacZ-sg-F / R, ΔwcaJ-sg-F / R, ΔpoxB-sg-F / R, and Δlon-sg-F / R to obtain pTargetF-sg-lacZ plasmids containing sgRNA targeting lacZ, pTargetF-sg-wcaJ plasmids containing sgRNA targeting wcaJ, pTargetF-sg-poxB plasmids containing sgRNA targeting poxB, and pTargetF-sg-lon plasmids containing sgRNA targeting lon gene. Each plasmid was transformed into competent E. coli JM109, and evenly spread on LB plates containing 50 μg / mL spectinomycin, cultured at 37°C overnight, and the plasmids were extracted and sequenced for verification.
[0089] 3. Take out E.coli BL21(DE3)-4 from -80℃ freezer, streak on LB solid medium, and culture at 37℃ overnight; pick a single colony and inoculate it into 5mL LB liquid medium, and culture it at 37℃ and 220rpm for 10-16h; transfer it to 50mL liquid LB medium at a ratio of 1%, and culture it at 37℃ and 220r / pm until OD 600nmWhen the pH value is 0.5-0.6, transfer to an ice box for an ice bath for 20-30 minutes, and then centrifuge at 4°C, 4000rpm / min for 10 minutes to collect the bacteria; discard the supernatant, resuspend the cells in an equal volume of pre-cooled sterile deionized water, and centrifuge at 4°C, 4000rpm / min for 10 minutes to collect the bacteria; discard the supernatant, wash three times with pre-cooled 10% (V / V) glycerol solution; discard the supernatant, add 2mL of pre-cooled 10% (V / V) glycerol solution to resuspend the cells, and dispense 50μL into centrifuge tubes and store at -80°C for later use.
[0090] 4. Take pCas9 plasmid and E.coli BL21(DE3)-4 competent cells, thaw on ice, add 5μL of pCas9 plasmid, mix gently, put in ice bath for 5min, transfer to an electroporation cup with a diameter of 1mm, put in an electroporator for electric shock, and adjust the electric shock parameters to 200Ω, 25μF, 2.5kV. After electric shock, immediately add 1mL of pre-cooled LB recovery medium, mix well, and transfer to a centrifuge tube; culture at 30℃, 180rpm for 1h; take 100μL of the recovery culture and spread it on a resistance plate containing 50μg / mL kanamycin, and culture it at 30℃ overnight, pick a single clone colony for colony PCR verification, and add culture medium to obtain E.coli BL21(DE3)-4 / pCas9 competent cells after verification.
[0091] 5. Mix 200ng of plasmid pTargetF-sg-lacZ and 400ng of homologous recombination fragment lacZ-UD in advance, electrotransform to E.coli BL21(DE3)-4 / pCas competent cells, and then evenly spread on a resistance plate containing 50μg / mL spectinomycin, and culture at 30℃ overnight; the next day, pick a single colony and inoculate it in LB liquid culture medium containing 50μg / mL kanamycin and 50μg / mL spectinomycin, and perform colony PCR identification. Through further sequencing confirmation, the engineered bacteria E.coliBL21(DE3)-4△lacZ with inactivated lacZ gene was obtained.
[0092] 6. Inoculate the successfully identified single colony into LB liquid culture medium containing 50μg / mL kanamycin, add 0.5mM IPTG to induce the expression of gRNA-pMB1 on the pCas9 plasmid, and culture at 30℃ overnight to eliminate the pTargetF-sg-lacZ plasmid. Continue to streak and isolate single clones on LB plates containing 50μg / mL kanamycin to obtain E.coli BL21(DE3)-4△lacZ (E.coli BL21(DE3)-4△lacZ / pCas) containing only the pCas9 plasmid.
[0093] 7. According to the same method, 200ng pTargetF-sg-wcaJ plasmid and 400ng homologous recombination fragment wcaJ-UD were mixed, and electroporated to E.coli BL21(DE3)-4△lacZ / pCas competent cells, and induced to eliminate pTargetF-sg-wcaJ plasmid, and E.coli BL21(DE3)-4△lacZ△wcaJ containing only pCas9 plasmid was obtained. Then 200ng pTargetF-sg-poxB plasmid and 400ng homologous recombination fragment poxB-UD were mixed, and electroporated to E.coliBL21(DE3)-4△lacZ△wcaJ / pCas competent cells, and induced to eliminate pTargetF-sg-poxB plasmid, and E.coli BL21(DE3)-4△lacZ△wcaJ△poxB containing only pCas9 plasmid was obtained. Finally, 200 ng of pTargetF-sg-lon plasmid and 400 ng of homologous recombination fragment lon-UD were mixed and electroporated into E. coli BL21 (DE3) -4△lacZ△wcaJ△poxB / pCas competent cells, which were induced to eliminate the pTargetF-sg-lon plasmid to obtain E. coli BL21 (DE3) -4△lacZ△wcaJ△poxB△lon containing only the pCas9 plasmid, which was recorded as E. coli BL21 (DE3) -5.
[0094] Example 5: Construction of E. coli BL21(DE3)-8 strain
[0095] 1. Construction of E. coli BL21(DE3)-6 strain
[0096] Based on the E. coli BL21 (DE3) -5 strain, the zwf and prs genes on the pentose phosphate pathway (PPP) were overexpressed to increase the supply of NADPH, and the E. coli BL21 (DE3) -6 strain was obtained. The specific steps are as follows:
[0097] 1. Using E. coli BL21 (DE3) genomic DNA as a template, PCR amplification was performed using primers zwf-F / R and prs-F / R to obtain zwf gene fragments and prs gene fragments, respectively.
[0098] 2. The zwf gene fragment and pCDF-Duet plasmid were double-digested with EcoRI / BamHI. After the digestion product was purified by gel recovery, the obtained gene fragment and the pCDF-Duet plasmid digestion fragment were connected overnight using DNA ligase. The ligation product was transformed into E.coli JM109 competent state by heat shock, screened with streptomycin resistance plates, and the transformants were selected for sequencing verification to obtain a successfully constructed plasmid, which was recorded as pCDF-Duet-zwf.
[0099] The prs gene fragment and the pCDF-Duet-zwf plasmid were double digested with KpnI / XhoI. After the digestion product was recovered and purified by gel, the obtained gene fragment and the pCDF-Duet-zwf plasmid digestion fragment were connected overnight using DNA ligase; the ligation product was heat-shock transformed into E.coli JM109 competent state, screened on streptomycin resistance plates, and the transformants were selected for sequencing verification to obtain a successfully constructed plasmid, which was recorded as pCDF-Duet-zwf-prs.
[0100] 3. Transform the above plasmid pCDF-Duet-zwf-prs into E. coli BL21 (DE3)-5 to obtain the engineered bacteria E. coli BL21 (DE3)-6.
[0101] 2. Construction of E. coli BL21(DE3)-7 strain
[0102] Based on the E. coli BL21 (DE3) -6 strain, the GTP regeneration pathway genes (gsk, gpt, gmk, ndk) and their upstream purine operon genes (purF, purHD, purC, purMN, purL, purEK) were overexpressed to obtain the E. coli BL21 (DE3) -7 strain. The specific steps are as follows:
[0103] 1. Overexpression of GTP regeneration pathway and its upstream purine operon genes
[0104] Using E. coli BL21 (DE3) genomic DNA as template, PCR amplification was performed with primers gsk-F / R, gpt-F / R, gmk-F / R, ndk-F / R, purF-F / R, purHD-F / R, purC-F / R, purMN-F / R, purL-F / R and purEK-F / R to obtain gsk gene fragment, gpt gene fragment, gmk gene fragment, ndk gene fragment, purF gene fragment, purHD gene fragment, purC gene fragment, purMN gene fragment, purL gene fragment and purEK gene fragment, respectively.
[0105] 2. The gsk gene fragment and pCDF-Duet plasmid were double-digested with BamHI / EcoRI. After the digestion product was recovered and purified by gel, the obtained gene fragment and the pCDF-Duet plasmid digestion fragment were connected overnight using DNA ligase; the ligation product was transformed into E. coli JM109 competent state by heat shock, screened on streptomycin resistance plates, and the transformants were selected for sequencing to obtain a successfully constructed plasmid, which was recorded as pCDF-Duet-gsk.
[0106] The gpt gene fragment and the pCDF-Duet-gsk plasmid were double digested with HindIII / NotI, and the digested products were recovered and purified by gel, and then the gpt gene fragment and the pCDF-Duet-gsk plasmid digested fragment were connected overnight using DNA ligase; the ligation product was heat-shock transformed into E. coli JM109 competent state, screened on streptomycin resistance plates, and the transformants were selected for sequencing verification to obtain a successfully constructed plasmid, which was recorded as pCDF-Duet-gsk-gpt.
[0107] The gmk gene fragment and the pCDF-Duet-gsk-gpt plasmid were double-digested with NdeI / EcoRV, and the digestion product was recovered and purified by gel, and then the gmk gene fragment and the pCDF-Duet-gsk-gpt plasmid digestion fragment were connected overnight using DNA ligase; the ligation product was heat-shock transformed into E. coli JM109 competent state, screened on streptomycin resistance plates, and the transformants were picked for sequencing verification to obtain a successfully constructed plasmid, which was recorded as pCDF-Duet-gsk-gpt-gmk.
[0108] The ndk gene fragment and the pCDF-Duet-gsk-gpt-gmk plasmid were double-digested with KpnI / XhoI, and the digestion product was recovered and purified by gel, and then the obtained gene fragment and the pCDF-Duet-gsk-gpt-gmk plasmid digestion fragment were connected overnight using DNA ligase; the ligation product was heat-shock transformed into E.coli JM109 competent state, screened on streptomycin resistance plates, and the transformants were selected for sequencing verification to obtain a successfully constructed plasmid, which was recorded as pCDF-Duet-gsk-gpt-gmk-ndk.
[0109] The purF gene fragment and the pACYC-Duet plasmid were double-digested with BamHI / EcoRI. The digestion product was recovered and purified by gel recovery. The obtained gene fragment and the pACYC-Duet plasmid digestion fragment were treated overnight with DNA ligase. The ligation product was transformed into E. coli JM109 competent cells by heat shock and screened on streptomycin resistance plates. The transformants were picked for sequencing verification to obtain a successfully constructed plasmid, which was recorded as pACYC-Duet-purF.
[0110] The purHD gene fragment and the pACYC-Duet-purF plasmid were double digested with HindIII / NotI. The digestion products were recovered and purified by gel recovery. The purHD gene fragment and the pACYC-Duet-purF plasmid digestion fragment were treated overnight with DNA ligase. The ligation products were transformed into E. coli JM109 competent cells by heat shock and screened on streptomycin resistance plates. The transformants were selected for sequencing and verification to obtain a successfully constructed plasmid, which was recorded as pACYC-Duet-purF-purHD.
[0111] The purC gene fragment and the pACYC-Duet-purF-purHD plasmid were double-digested with NdeI / EcoRV. The digestion products were recovered and purified by gel recovery. The purC gene fragment and the pACYC-Duet-purF-purHD plasmid digestion fragment were treated overnight with DNA ligase. The ligation products were heat-shock transformed into E. coli JM109 competent cells and screened on streptomycin resistance plates. The transformants were picked for sequencing verification to obtain a successfully constructed plasmid, which was recorded as pACYC-Duet-purF-purHD-purC.
[0112] The purMN gene fragment and the pACYC-Duet-purF-purHD-purC plasmid were double digested with EcoRV / XhoI. The digestion products were purified by gel recovery. The purMN gene fragment and the pACYC-Duet-purF-purHD-purC plasmid digestion fragment were treated overnight with DNA ligase. The ligation products were transformed into E. coli JM109 competent cells by heat shock and screened on streptomycin resistance plates. The transformants were picked for sequencing verification to obtain a successfully constructed plasmid, which was recorded as pACYC-Duet-purF-purHD-purC-purMN.
[0113] The purL gene fragment and the pETDuet-1 plasmid (Shanghai Kelei Biotechnology Co., Ltd., catalog number kl-zl-1053-01) were double-digested with SacI / AscI, and the digestion product was purified by gel recovery. The purL gene fragment and the pETDuet-1 plasmid digestion fragment were treated overnight with DNA ligase, and the ligation product was transformed into E. coli JM109 competent state by heat shock, screened on ampicillin resistance plates, and the transformants were selected for sequencing to obtain a successfully constructed plasmid, which was recorded as pETDuet-purL.
[0114] The purEK gene fragment and the pETDuet-purL plasmid were double digested with NedI / XhoI. After the digestion product was recovered and purified by gel, the purEK gene fragment and the pETDuet-purL plasmid digestion fragment were treated overnight with DNA ligase. The ligation product was transformed into E. coli JM109 competent state by heat shock, screened with ampicillin resistance plates, and the transformants were selected for sequencing to obtain a successfully constructed plasmid, which was recorded as pETDuet-purL-purEK.
[0115] 3. The above plasmids pCDF-Duet-gsk-gpt-gmk-ndk, pACYC-Duet-purF-purHD-purC-purMN and pETDuet-purL-purEK were transformed into E. coli BL21 (DE3)-6 to obtain E. coli BL21 (DE3)-7 strain.
[0116] 3. Construction of E. coli BL21(DE3)-8 strain
[0117] Based on the E. coli BL21 (DE3) -7 strain, the purR gene was deleted (knocked out) and the purA gene was weakened (the promoter of the purA gene was replaced with the fliC promoter PfliC) to obtain the E. coli BL21 (DE3) -8 strain. The specific steps are as follows:
[0118] 1. Deletion of purR gene
[0119] 1) Using E. coli BL21 (DE3) genomic DNA as a template, PCR amplification was performed with primers purR-F / R to obtain the purR gene fragment, and the DNA fragment was recovered by gel. Using pTargetF plasmid as a template, PCR amplification was performed with primers ΔpurR-sg-F / R to obtain the pTargetF-sg-purR plasmid with the targeted purR gene. The pTargetF-sg-purR plasmid was transformed into competent E. coli JM109, evenly spread on LB plates containing 50 μg / mL spectinomycin, cultured at 37°C overnight, and the plasmid was extracted and sequenced for verification.
[0120] 2) 200 ng of plasmid pTargetF-sg-purR and 400 ng of purR gene fragment were mixed in advance, electroporated into E. coli BL21 (DE3) -7 / pCas9 competent cells, and then evenly spread on a resistance plate containing 50 μg / mL spectinomycin, and cultured overnight at 30 ° C; the next day, a single colony was picked and inoculated into LB liquid culture medium containing 50 μg / mL kanamycin and 50 μg / mL spectinomycin, and colony PCR was performed for identification. Through further sequencing confirmation, the engineered bacteria E. coli BL21 (DE3) -7 △ purR with purR gene deletion was obtained.
[0121] 3) Inoculate the successfully identified single colony into LB liquid culture medium containing 50μg / mL kanamycin, add 0.5mM IPTG to induce the expression of gRNA-pMB1 on the pCas9 plasmid, and culture at 30℃ overnight to eliminate the pTargetF-sg-purR plasmid. Continue to streak and isolate single clones on LB plates containing 50μg / mL kanamycin to obtain E.coliBL21(DE3)-7△purR containing only the pCas9 plasmid.
[0122] 2. Weakening the purA gene
[0123] 1) Using E. coli BL21 (DE3) genomic DNA as a template, primers purA-F / R were used for PCR amplification to obtain the upstream and downstream homology arms P1 and P2 of the purA gene promoter and the fliC promoter PfliC; plasmid pKD13 (Shanghai Lianmai Bioengineering Co., Ltd., catalog number LM2053) was used as a template to amplify the selection marker resistance gene Kan. Then, the four fragments (the upstream and downstream homology arms P1 and P2 of the purA gene promoter, the fliC promoter PfliC and the selection marker resistance gene Kan) were assembled using fusion PCR technology to obtain P1-Kan-PfliC-P2. The nucleotide sequence of P1-Kan-PfliC-P2 is shown in SEQ ID NO: 40, wherein positions 1-1000 are the upstream homology arm P1, positions 1001-1809 are Kan, positions 1810-1838 are PfliC, and positions 1839-2838 are the downstream homology arm P2.
[0124] 2) The plasmid pKD46 (Shanghai Lianmai Biotechnology Co., Ltd., catalog number LM1692) was transformed into E. coli BL21 (DE3) -7△purR competent cells to obtain E. coli BL21 (DE3) -7△purR / pKD46 competent cells. The integration fragment P1-Kan-PfliC-P2 obtained above was electroporated into E. coli BL21 (DE3) -7△purR / pKD46 competent cells, and a single clone was picked to verify whether the promoter modification was correct by colony PCR, and further sequenced for verification.
[0125] 3) The correctly transformed strain was cultured overnight at 37°C, streaked on an LB plate, and when a single colony grew out, it was spotted on a plate without ampicillin resistance and a plate containing ampicillin resistance. Bacteria that grew on the plate without ampicillin resistance but not on the plate containing ampicillin resistance indicated that the auxiliary plasmid pKD46 had been successfully eliminated.
[0126] 4) The resistance gene was removed using the auxiliary plasmid pCP20, and the strain that had successfully eliminated the plasmid pKD46 was transformed into the temperature-sensitive plasmid pCP20 (Beijing Zhuangmeng International Biogene Technology Co., Ltd., catalog number ZK1660). After picking a single colony for overnight culture, it was transferred into a 250 mL Erlenmeyer flask containing 20 mL LB medium at a 1% (v / v) inoculation volume and cultured at 30°C until OD 600nm When the p-value is 0.1, culture at 42°C for more than 12 hours, then streak the bacterial solution on an LB plate without resistance, pick out a single clone, and spot it on LB plates without resistance, containing ampicillin resistance, and containing kanamycin resistance, respectively, to verify whether the resistance gene and pCP20 plasmid were successfully removed. The successfully verified strain was E. coli BL21(DE3)-8.
[0127] Example 6: Synthesis of 2′-FL by engineered E. coli in shake flask fermentation
[0128] Test strains: E.coli BL21(DE3)-1, E.coli BL21(DE3)-2, E.coli BL21(DE3)-3, E.coli BL21(DE3)-5, E.coli BL21(DE3)-8.
[0129] Inoculate the test strains into LB medium containing the corresponding antibiotics, pick colonies of each strain from the plate and inoculate them into 4 mL LB medium. After overnight culture, inoculate 0.5 mL of the culture into 25 mL DM medium containing antibiotics for the corresponding plasmid. Cultivate in a 250 mL shake flask at 200 rpm and 37 °C. When the cell OD 600nmWhen the pH value reached 0.6-0.8, IPTG was added to a final concentration of 0.5 mM and the substrates lactose (final concentration of 5 g / L) and L-fucose (final concentration of 2 g / L) were added. The culture was carried out at 25°C, and the fermentation broth was collected after 72 hours to detect the 2′-FL production using HPLC.
[0130] The yield detection method of 2′-FL is as follows: first, the fermentation broth is centrifuged (8,000 rpm for 10 minutes), 1 mL of the fermentation broth supernatant is collected, and then the supernatant is analyzed by HPLC using a high performance liquid chromatograph (Agilent 1260) and an organic acid chromatography column (Rezex ROA-OrganicAcid H+column). The mobile phase is a 5 mM sulfuric acid aqueous solution, the flow rate is 0.6 mL / min, and the column temperature is 60°C.
[0131] The results are shown in Table 2. The results showed that the 2′-FL production of E. coli BL21(DE3)-8 strain could reach 11.1 g / L after 72 hours of fermentation in a shake flask.
[0132] Table 2. Detailed information and yield of each engineered bacteria and its transformation
[0133]
[0134]
[0135] Example 7: Fermentation of 2′-FL by engineered E. coli in a 5 L tank
[0136] The engineered bacteria E.coli BL21 (DE3) -8 was inoculated into LB medium containing the corresponding antibiotics, cultured at 37°C, 200rpm / min for 12h, transferred to a 5L fermenter containing DM medium, cultured at 37°C, 300-750rpm until glycerol was exhausted, added with IPTG at a final concentration of 0.1mM and substrate lactose at a final concentration of 5g / L, and added with a uniform flow mode, with a glycerol feed rate of 4.5-11.0g / L / h and a lactose feed rate of 1.5-3.0g / L / h, and the temperature was lowered to 25°C for fermentation, and continued fermentation, and then added with a final concentration of 20mM L-fucose once every 12h, for a total of 4 times. During the entire fermentation process, 50% ammonia water was used to regulate the pH to maintain at 6.5-7.0. After inducing fermentation, samples were taken at fixed time periods, and the amount of 2′-FL produced by the engineered bacteria E. coli BL21(DE3)-8 of the present invention was detected by HPLC.
[0137] The results showed that after fermentation in a 5L fermenter for 72 hours, the 2′-FL production of E. coli BL21(DE3)-8 strain could reach 46 g / L.
[0138] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.
Claims
1. A method for constructing a recombinant bacterium producing 2′-fucosyllactose, comprising: manA Gene, manB Gene, manC Gene, gmd Gene, flc Genes and futC Steps for introducing genes into E. coli; The method further comprises the steps of: fL Gene replacement with Wj gene, and the Escherichia coli motA Gene replacement with Wlq gene, and the Escherichia coli f Gene replacement with Wcfb Gene; Said manA The sequence of the gene is shown as Sequence 1 in the sequence listing; Said manB The sequence of the gene is shown as Sequence 2 in the sequence listing; Said manC The sequence of the gene is shown as Sequence 3 in the sequence listing; Said gmd The sequence of the gene is shown as Sequence 4 in the sequence listing; Said flc The sequence of the gene is shown as Sequence 5 in the sequence listing; Said futC The sequence of the gene is shown as Sequence 6 in the sequence listing; Said fL The sequence of the gene is shown as Sequence 7 in the sequence listing; Said Wj The sequence of the gene is shown as sequence 8 in the sequence listing; Said motA The sequence of the gene is shown as Sequence 9 in the sequence listing; Said Wlq The sequence of the gene is shown as sequence 10 in the sequence listing; Said f The sequence of the gene is shown as sequence 11 in the sequence listing; Said Wcfb The sequence of the gene is shown as Sequence 12 in the sequence listing.
2. The construction method according to claim 1, Features: The method further comprises the steps of: fL Gene, motA Genes and f Genes were replaced by futC Gene.
3. The construction method according to claim 2, Features: The method further comprises the steps of: knocking out the lacZ Gene, wxya Gene, poxB Genes and lon gene, and the Escherichia coli treB Gene replacement with lac12 Gene; Said lacZ The sequence of the gene is shown as sequence 13 in the sequence listing; Said wxya The sequence of the gene is shown as sequence 14 in the sequence listing; Said poxB The sequence of the gene is shown as sequence 15 in the sequence listing; Said lon The sequence of the gene is shown as sequence 16 in the sequence listing; Said treB The sequence of the gene is shown as sequence 17 in the sequence listing; Said lac12 The sequence of the gene is shown as Sequence 18 in the sequence listing.
4. The construction method according to claim 3, Features: The method further comprises the steps of: wxya Gene, prs Gene, gsk Gene, gpt Gene, gmk Gene, ndk Gene, F Gene, purHD Gene, purC Gene, purMN Gene, pl Genes and purEK The gene is introduced into the Escherichia coli, and the Escherichia coli in the purR gene, and weaken the E. coli purA Gene; Said wxya The sequence of the gene is shown as sequence 19 in the sequence listing; Said prs The sequence of the gene is shown as sequence 20 in the sequence listing; Said gsk The sequence of the gene is shown as sequence 21 in the sequence listing; Said gpt The sequence of the gene is shown as sequence 22 in the sequence listing; Said gmk The sequence of the gene is shown as sequence 23 in the sequence listing; Said ndk The sequence of the gene is shown as sequence 24 in the sequence listing; Said F The sequence of the gene is shown as sequence 25 in the sequence listing; Said purHD The sequence of the gene is shown as sequence 26 in the sequence listing; Said purC The sequence of the gene is shown as sequence 27 in the sequence listing; Said purMN The sequence of the gene is shown as sequence 28 in the sequence listing; Said pl The sequence of the gene is shown as sequence 29 in the sequence listing; Said purEK The sequence of the gene is shown as sequence 30 in the sequence listing; Said purR The sequence of the gene is shown as sequence 31 in the sequence listing; Said purA The sequence of the gene is shown as sequence 32 in the sequence listing.
5. The construction method according to any one of claims 1 to 4, Features: The Escherichia coli is E . coli BL21(DE3) strains.
6. The recombinant bacterium constructed by the construction method according to any one of claims 1 to 5.
7. Any application as described in M1) to M4) below: M1) Use of the recombinant bacteria according to claim 6 in the production of 2′-fucosyllactose; M2) Use of the recombinant bacteria according to claim 6 in increasing the production of 2′-fucosyllactose; M3) Use of the recombinant bacteria according to claim 6 in the preparation of a product for producing 2′-fucosyllactose; M4) Use of the recombinant bacteria according to claim 6 in the preparation of a product with increased 2′-fucosyllactose production.
8. A method for producing 2'-fucosyllactose, comprising the following steps: fermenting and culturing the recombinant bacteria according to claim 6 to obtain a fermentation product, wherein the fermentation product contains 2'-fucosyllactose.
